Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
about
Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1Liver tumors in children with metabolic disordersRecommendations for the management of tyrosinaemia type 1Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogensMechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitorComplete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathwayPharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteersLiver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cellsA universal system to select gene-modified hepatocytes in vivoPoint mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1The C-terminal of rat 4-hydroxyphenylpyruvate dioxygenase is indispensable for enzyme activity4-hydroxyphenylpyruvate dioxygenase catalysis: identification of catalytic residues and production of a hydroxylated intermediate shared with a structurally unrelated enzymeCurative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.Who needs a liver transplant? (new disease specific indications).Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation.Fungal metabolic model for human type I hereditary tyrosinaemia.Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver diseasePharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU)Innovative therapy for Classic Galactosemia - tale of two HTS.Hereditary tyrosinaemia type I: from basics to progress in treatment.Transcriptome analysis of Paracoccidioides brasiliensis cells undergoing mycelium-to-yeast transitionMaleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism.Mechanisms of liver injury relevant to pediatric hepatology.Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.Pediatric liver transplantation in metabolic disease: clinical decision making.The origin and liver repopulating capacity of murine oval cells.Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.Managing liver failure.In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.Kinetics of liver repopulation after bone marrow transplantation.Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytesGeographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1Development and rescue of human familial hypercholesterolaemia in a xenograft mouse modelRelationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with AlkaptonuriaExperience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in LibyaHepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.Advances in genetics: what are the benefits for patients?Rodent models of alcoholic liver disease: of mice and men.Alkaptonuria: leading to the treasure in exceptions.
P2860
Q24672848-D3908824-C02B-4387-865F-C518CEBD3B48Q26770292-C8C76421-BABA-47D9-AFA1-55144F27F147Q26851571-8BE496B3-964D-4FA4-A632-DC7AFF04942FQ27487009-4C1AB277-346B-4ECF-90E6-BE58FA3C4F1EQ27629252-C4B53BD1-8C63-4788-9A46-D3BCE2FE06D9Q28119001-61CC2821-5F68-4CC2-AC3D-3FE9399906F1Q28345551-EC972D6E-B8F4-4C93-9EF7-EF9842C58D71Q28346158-C7E16762-49C7-45F4-A2AA-7D0D194B16EBQ28468539-3B3CAEE8-AEAF-47A4-A431-8F20EFB58AD8Q28510201-5094BFBB-5C71-444A-BC58-DAA95A72FA03Q28577879-FE946058-931C-4469-8E85-30AEE3205D3DQ30502554-359BA2E5-ED04-4955-9293-98339B91B48CQ30856034-007D8E80-73D6-45CB-8582-732FDDAB3650Q33588074-ED745FFE-A6E8-4A84-BA91-3BDA28AC6A69Q33591929-4E81B6B4-226D-4E62-AE3B-7F6613A14784Q33624749-0FC6115B-5E0C-43EA-ADDE-1155245C102CQ33887444-60740DB8-B032-4997-940C-E7D9A90D0EE6Q33897291-090A4FF4-F8A3-4D14-B022-9F91BDF9BCFEQ33993821-9F617689-F1D2-4D6C-A245-120FE4C6BA05Q34054239-83FDE6AD-6A64-4F8E-AF55-0E647877B815Q34111877-D34B727A-848D-48E0-BF46-982FE13C0D83Q34232855-60A10D0D-BC94-4466-A3C1-8DE0D22E516CQ34283083-E3DDD169-C92E-4E4E-ACFA-D3BAFC6BA845Q34559789-E1AC539F-2ACA-41E3-979B-585E662CFEAFQ34560227-0F9F7733-F601-4DDE-9DCB-8E98C39218D7Q34572731-14FAC337-A48F-4FC9-BDF7-2711EB38FBE6Q34582398-C6D7FD7D-B0F1-4867-8ED8-D221BEA36574Q34590786-9691FD3B-C61F-4CCC-91F0-CB9745F59B84Q35032212-F81C42A6-C191-4C2D-AEAE-93712C4367ACQ35723184-E687EC95-A55B-438B-B0B6-AEC4FA99D717Q35747636-B6B0F0CA-D7C0-4959-9DB0-DF7521C65328Q35764088-B889FF68-B5C2-45B9-AA2E-8732D8A2D8DDQ35848690-ED267F42-E244-4AE0-8102-09787749AF89Q36018639-67F5F862-A64F-4B36-838B-F0B268F08D3DQ36090577-2FFC2D98-EEB7-4C0F-B9B4-4C745630CF6DQ36175625-197C7797-091E-4D56-8BCE-F44EFB8C372FQ36266189-1146C78A-681C-42C1-9446-CDC4DB163927Q36337173-8901573E-21E9-4B46-A58E-132BAF4916EFQ36395131-ACB72303-AA48-4E52-99B1-EDA6C067124BQ36433474-A62FBF01-73D3-49EC-B100-FA10BBE47185
P2860
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@en
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@nl
type
label
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@en
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@nl
prefLabel
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@en
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@nl
P2093
P1433
P1476
Treatment of hereditary tyrosi ...... oxyphenylpyruvate dioxygenase.
@en
P2093
B Strandvik
O Hjalmarson
S Lindstedt
P304
P356
10.1016/0140-6736(92)92685-9
P407
P577
1992-10-01T00:00:00Z